TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s share price dropped 3.6% on Monday . The company traded as low as $3.22 and last traded at $3.23. 97,864 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 32,220,806 shares. The stock had previously closed at $3.35.
TNF Pharmaceuticals Stock Down 11.8%
The stock has a fifty day moving average of $3.79 and a two-hundred day moving average of $3.90. The stock has a market cap of $5.25 million, a price-to-earnings ratio of -0.01 and a beta of 2.04.
TNF Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Featured Articles
- Five stocks we like better than TNF Pharmaceuticals
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
